December 18, 2014
Developing New Tuberculosis Drugs from Marine Natural Products: Joint research program between OPBIO and TB Alliance announced
November 9, 2014
Summary of TB Alliance & UNITAID symposium on the Pediatric TB Drug Market (full presentations available)
October 21, 2014
TB Alliance Launches Phase 2B Clinical Trial of a Novel TB Drug Regimen that Could Cut Treatment Time by Half or More for a Majority of TB Patients
NC-005 trial tests a novel regimen of bedaquiline (Sirturo), pretomanid (formerly known as PA-824), and pyrazinamide; results could pave the way for a three-month TB treatment
October 20, 2014
PA-824 has a New Generic Name: Pretomanid
October 20, 2014
Community Engagement Forum Brings Sites and Researchers Together to Improve Efforts
New tools to improve communication, monitoring, and coordination introduced
September 6, 2014
Results of Phase 3 Clinical Trial of New Tuberculosis Drug Regimen Published in New England Journal of Medicine
August 18, 2014
Novartis Provides Drug Candidate Compounds to TB Alliance
Exclusive worldwide license from Novartis includes a novel class of drugs that is active against drug sensitive and multi-resistant strains of tuberculosis
July 30, 2014
TB Alliance Names Elana Robertson Senior Vice President, Market Access
Robertson Will Lead Initiatives to Accelerate Adoption of New TB Drug Regimens
July 30, 2014
TB Alliance Appoints Willo Brock Senior Vice President, External Affairs
Brock Will Lead Resource Development, Advocacy, Community Engagement Efforts in Support of Promising Research Pipeline
July 8, 2014